Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
This study evaluates the individual, as well as relative and joint value of indices obtained from magnetic resonance imaging (MRI) patterns of brain atrophy (quantified by the SPARE-AD index), cerebrospinal fluid (CSF) biomarkers, APOE genotype, and cognitive performance (ADAS-Cog) in progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) within a variable follow-up period up to 6 years, using data from the Alzheimer's Disease Neuroimaging Initiative-1 (ADNI-1). SPARE-AD was first established as a highly sensitive and specific MRI-marker of AD vs. cognitively normal (CN) subjects (AUC = 0.98). Baseline predictive values of all aforementioned indices were then compared using survival analysis on 381 MCI subjects. SPARE-AD and ADAS-Cog were found to have similar predictive value, and their combination was significantly better than their individual performance. APOE genotype did not significantly improve prediction, although the combination of SPARE-AD, ADAS-Cog and APOE ε4 provided the highest hazard ratio estimates of 17.8 (last vs. first quartile). In a subset of 192 MCI patients who also had CSF biomarkers, the addition of Aβ1-42, t-tau, and p-tau181p to the previous model did not improve predictive value significantly over SPARE-AD and ADAS-Cog combined. Importantly, in amyloid-negative patients with MCI, SPARE-AD had high predictive power of clinical progression. Our findings suggest that SPARE-AD and ADAS-Cog in combination offer the highest predictive power of conversion from MCI to AD, which is improved, albeit not significantly, by APOE genotype. The finding that SPARE-AD in amyloid-negative MCI patients was predictive of clinical progression is not expected under the amyloid hypothesis and merits further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The WEKA data mining software: an update
Hall, M., Frank, E., Holmes, G., Pfahringer, B., Reutemann, P., & Witten, I. H. (2009) · ACM SIGKDD Explorations Newsletter · doi:10.1145/1656274.1656278 · Cited by 17,750
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“In addition to biomarkers of neurodegeneration (e.g. structural magnetic resonance imaging (sMRI)), the new research criteria for MCI incorporate the use of biomarkers of Aβ deposition to define MCI due to AD (Albert et al., 2011).”
BackgroundMethodHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Self-citationThe Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“10% or more of the cases with a clinical diagnosis of AD do not have an underlying AD when assessed in neuropathological studies (Nelson et al., 2012; Toledo et al., 2012) and this percentage increases in the MCI stage.”
BackgroundSelf-citationThe Alzheimer's Disease Neuroimaging Initiative
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.008 · Cited by 1,525
Self-citationMonetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“Alzheimer's Disease (AD) is the most common form of dementia and a major health and socioeconomic concern (Hurd et al., 2013); therefore, early detection and disease modifying drug development are critically important.”
BackgroundMild Cognitive Impairment: Ten Years Later
Petersen, R. C., Roberts, R. O., Knopman, D. S., Boeve, B. F., Geda, Y. E., Ivnik, R. J., Smith, G. E., & Jack, C. R. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.266 · Cited by 1,447
Automatic classification of MR scans in Alzheimer’s disease.
Kloppel, S., Stonnington, C. M., Chu, C., Draganski, B., Scahill, R. I., Rohrer, J. D., Fox, N. C., Jack, C. R., Ashburner, J., & Frackowiak, R. S. J. (2008) · Brain · doi:10.1093/brain/awm319 · Cited by 1,170
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958 · cited 2×
“…and the similar amyloid levels between amnesticmild cognitive impairment (aMCI) and CN individuals, despite respective hippocampal volumes being different (Jack et al., 2008b), albeit some studies have shown stronger association between amyloid deposition and atrophy patterns (Tosun et al., 2011).”
ResultThe neuropathology of probable Alzheimer disease and mild cognitive impairment
Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 2×
“Aβ deposition can be measured using PET tracers (Clark et al., 2012a; Ikonomovic et al., 2008) which correlate with decrease in Aβ1–42 in CSF (Fagan et al., 2009; Toledo et al., 2011).”
BackgroundTapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · cited 1×
“Because CSF biomarkers show a good correlation with AD pathology in the brain (Tapiola et al., 2009), it is possible that some amyloidnegative MCI individuals have a frontotemporal lobar degeneration and therefore these patients can show a different pattern of atrophy.”
BackgroundClark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855 · cited 4×
“Aβ deposition can be measured using PET tracers (Clark et al., 2012a; Ikonomovic et al., 2008) which correlate with decrease in Aβ1–42 in CSF (Fagan et al., 2009; Toledo et al., 2011).”
BackgroundMethodResultInfluentialSchuff, N., Woerner, N., Boreta, L., Kornfield, T., Shaw, L. M., Trojanowski, J. Q., Thompson, P. M., Jack, C. R., Weiner, M. W., & Initiative, T. A. D. N. (2008) · Brain · doi:10.1093/brain/awp007 · Cited by 679
Self-citationComparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616
Self-citationJack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602
MISRA, C., FAN, Y., & DAVATZIKOS, C. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.031 · Cited by 552
Self-citationFan, Y., Batmanghelich, N., Clark, C. M., & Davatzikos, C. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.10.031 · Cited by 477 · cited 3×
“…also complement several studies that used a specific follow-up time as cut-off for dichotomous conversion/stability outcome (Aksu et al., 2011; Fan et al., 2008; Kloppel et al., 2008; Plant et al., 2010; Vemuri et al., 2008, 2009b), albeit those results are not directly comparable to ours as…”
BackgroundMethodResultInfluentialSelf-citationBrain β-amyloid load approaches a plateau
Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406 · cited 2×
“It has been suggested that the presence of amyloid heightens the risk of conversion to AD, perhaps due to changes taking place in an early stage and followed by a ceiling effect (Jack et al., 2010a, 2013b).”
BackgroundTotal and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389 · cited 1×
“CSF concentrations have shown promise in predicting conversion from MCI to AD (Hampel et al., 2010a, 2010b; Schuff et al., 2009; Shaw et al., 2009).”
BackgroundSelf-citationDetection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imaging
Davatzikos, C., Fan, Y., Wu, X., Shen, D., & Resnick, S. M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.010 · Cited by 385 · cited 4×
“MRI-derived markers have been of central interest in characterizing brain structure in AD (Davatzikos et al., 2008a, 2008b, 2009; Fox and Schott, 2004; Jack et al., 2003; Kloppel et al., 2008; Schuff et al., 2009; Vemuri et al., 2009a; Wolz et al., 2011), and patterns of brain atrophy obtained from…”
BackgroundMethodResultInfluentialSelf-citationMRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment
Whitwell, J. L., Shiung, M. M., Przybelski, S. A., Weigand, S. D., Knopman, D. S., Boeve, B. F., Petersen, R. C., & Jack, C. R. (2008) · Neurology · doi:10.1212/01.wnl.0000280575.77437.a2 · Cited by 357 · cited 1×
“4) was in agreement with other literature in the field using analogous methods (Whitwell et al., 2008).”
ResultFagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353
McEvoy, L. K., Fennema-Notestine, C., Roddey, J. C., Hagler, D. J., Holland, D., Karow, D. S., Pung, C. J., Brewer, J. B., & Dale, A. M. (2009) · Radiology · doi:10.1148/radiol.2511080924 · Cited by 330
Davatzikos, C., Xu, F., An, Y., Fan, Y., & Resnick, S. M. (2009) · Brain · doi:10.1093/brain/awp091 · Cited by 315
Self-citationWalhovd, K. B., Fjell, A. M., Brewer, J., McEvoy, L. K., Fennema-Notestine, C., Hagler, D. J., Jennings, R. G., Karow, D., Dale, A. M., & Initiative, T. A. D. N. (2010) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1809 · Cited by 279
Wolk, D. A., Dickerson, B. C., Initiative, T. A. D. N., Weiner, M., Aiello, M., Aisen, P., Albert, M. S., Alexander, G., Anderson, H. S., Anderson, K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001412107 · Cited by 248
Self-citationCSF biomarkers cutoffs: The importance of coincident neuropathological diseases
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182 · cited 2×
“10% or more of the cases with a clinical diagnosis of AD do not have an underlying AD when assessed in neuropathological studies (Nelson et al., 2012; Toledo et al., 2012) and this percentage increases in the MCI stage.”
BackgroundSelf-citationLongitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
Toledo, J. B., Xie, S. X., Trojanowski, J. Q., & Shaw, L. M. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1151-4 · Cited by 180 · cited 3×
“In addition, several different pathologies can be present in a single subject as we recently described in a small subset of ADNI subjects that came to autopsy that coincident pathologies are a common finding (Toledo et al., 2013a).”
BackgroundSelf-citationWirth, M., Madison, C. M., Rabinovici, G. D., Oh, H., Landau, S. M., & Jagust, W. J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4409-12.2013 · Cited by 151
Cited by
Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects
Moradi, E., Pepe, A., Gaser, C., Huttunen, H., & Tohka, J. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2014.10.002 · Cited by 708
Rathore, S., Habes, M., Iftikhar, M. A., Shacklett, A., & Davatzikos, C. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.03.057 · Cited by 622
“For example, SPARE-AD was combined with cognitive scores, APOE genotype, and CSF biomarkers (Da et al., 2014) to predict conversion from MCI to AD.”
Self-citationWhite matter hyperintensities and imaging patterns of brain ageing in the general population
Habes, M., Erus, G., Toledo, J. B., Zhang, T., Bryan, N., Launer, L. J., Rosseel, Y., Janowitz, D., Doshi, J., Van der Auwera, S., et al. (2016) · Brain · doi:10.1093/brain/aww008 · Cited by 422
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
“In a follow-up study, Da et al [500] found that the inclusion of neither APOE status nor CSF biomarkers significantly improved the prediction, although ADAS-cog was equally effective as SPARE-AD alone in predicting time to conversion.”
MethodSelf-citationNeuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease
Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00395-3 · Cited by 265
Metadata
- Authors
- Da, X., Toledo, J. B., Zee, J., Wolk, D. A., Xie, S. X., Ou, Y., Shacklett, A., Parmpi, P., Shaw, L., Trojanowski, J. Q., & Davatzikos, C.
- Venue
- NeuroImage: Clinical
- Publisher
- Elsevier BV
- Published
- 2014
- Volume
- 4
- Pages
- 164-173
- ISSN
- 2213-1582 (ISSN-L)
- OpenAlex
- W2009110843
- Cited by
- 135
- References
- 35
- FWCI
- 8.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.